Based on immunoblotting and ELISA, this antibody shows approximately 2% cross-reactivity with recombinant mouse VEGF Receptor 1, and no cross-reactivity with recombinant human VEGF Receptor 1 and VEGF Receptor 3.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 5 - 15 µg/ml. (and tissues).
Use a concentration of 0.5 - 1 µg/ml.
Use at an assay dependent concentration. PubMed: 20882677
Use a concentration of 3 - 10 µg/ml.
ab37373 - Goat polyclonal IgG, is suitable for use as an isotype control with this antibody.
Use at an assay dependent concentration. See Abreview.
Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 152 kDa.
Use at an assay dependent concentration.
Use at an assay dependent concentration. PubMed: 20884890
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Involvement in disease
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. Contains 7 Ig-like C2-type (immunoglobulin-like) domains. Contains 1 protein kinase domain.
Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
Wang TC et al. Characterization of highly proliferative secondary tumor clusters along host blood vessels in malignant glioma. Mol Med Rep12:6435-44 (2015).
Read more (PubMed: 26299849) »
Soda Y et al. From the Cover: Feature Article: Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A108:4274-80 (2011).
Read more (PubMed: 21262804) »